Pediatric respiratory infections by Mycoplasma pneumoniae

Expert Review of Anti-Infective Therapy

Volumn 6, Issue 4, 2008, Pages 509-521

  Lee, Kyung Yil ^a  

^a Daejeon St Mary's Hospital   (South Korea)

Author keywords

Antiobiotic; Children; Corticosteroid; Intravenous immunoglobulin; Macrolide; Mycoplasma pneumonia; Pneumonia

Indexed keywords

BETA LACTAM; CEPHALOSPORIN; CORTICOSTEROID; IMMUNOGLOBULIN; MACROLIDE; PENICILLIN G; PREDNISOLONE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE;

ADJUVANT THERAPY; ANTIINFLAMMATORY ACTIVITY; CLINICAL FEATURE; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; COUGHING; FEVER; HEADACHE; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; INCIDENCE; MALAISE; MYCOPLASMA PNEUMONIA; MYCOPLASMA PNEUMONIAE; NONHUMAN; POLYMERASE CHAIN REACTION; RESPIRATORY TRACT INFECTION; REVIEW; SEROLOGY; SEROPREVALENCE; SORE THROAT; CHILD; COMMUNICABLE DISEASE; CYTOLOGY; EPIDEMIC; MICROBIOLOGY; PHYSIOLOGY;

CHILD; COMMUNITY-ACQUIRED INFECTIONS; DISEASE OUTBREAKS; HUMANS; MYCOPLASMA PNEUMONIAE; PNEUMONIA, MYCOPLASMA;

EID: 54449099201     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.6.4.509     Document Type: Review

References (162)

1. Broughton RA. Infections due to Mycoplasma pneumoniae in childhood. Pediatr Infect. Dis. J. 5(1), 71-85 (1986).
2. Ferwerda A, Moll HA, de Groot R. Respiratory tract infections by Mycoplasma pneumoniae in children: a review of diagnostic and therapeutic measures. Eur. J. Pediatr. 160(8), 483-491 (2001).
3. Waites KB, Talkington DE. Mycoplasma pneumoniae and its role as a human pathogen. Clin. Microbiol. Rev. 17(4), 697-728 (2004).
4. Marston BJ, Plouffe JF, File TM Jr et al. Incidence of community-acquired pneumonia requiring hospitalization: results of a population-based active surveillance study in Ohio. The Community-Based Pneumonia Incidence Study Group. Arch. Intern. Med. 157(15), 1709-1718 (1997).
5. Ngeow YF, Suwanjuta S, Chantarojanasriri T et al. An Asian study on the prevalence of atypical respiratory pathogens in community-acquired pneumonia. Int. J. Infect. Dis. 9(3), 144-153 (2005).
6. Michelow IC, Olsen K, Lozano J et al. Epidemiology and clinical characteristics of community acquired pneumonia in hospitalized children. Pediatrics 113(4), 701-707 (2004).
7. Korppi M, Heinskanen-Kosma T, Kleemola M. Incidence of community-acquired pneumonia in children caused by Mycoplasma pneumoniae: serologic results of a prospective, population based study in primary health care. Respirology 9(1), 109-114 (2004).
8. Chiang WC, Teoh OH, Chong CY, Goh A, Tang JP, Chay OM. Epidemiology, clinical characteristics and antimicrobial resistance patterns of community-acquired pneumonia in 1702 hospitalized children in Singapore. Respirology 12(2), 254-261 (2007).
9. Holt PG, Jones CA. The development of the immune system during pregnancy and early life. Allergy 55(8), 688-697 (2000).
10. Lee KY, Lee HS, Hong JH et al. Role of prednisolone treatment in severe Mycoplasma pneumoniae pneumonia in children. Pediatr. Pulmonol. 41(3), 263-268 (2006).
11. Lee KY, Lee HS, Hong JH et al. Author reply. Pediatr. Pulmonol. 41(10), 1010 (2006).
12. Lee SH, Noh SM, Lee KY et al. Clinico-epidemiologic study of Mycoplasma pneumonia pneumonia (1993 through 2003). J. Korean Pediatr. 48(2), 154-157 (2005).
13. Chan ED, Welsh CH. Fulminant Mycoplasma pneumoniae pneumonia. West. J. Med. 162(2), 133-142 (1995).
14. Razin S, Yogev D, Naot Y. Molecular biology and pathogenesity of mycoplasmas. Microbiol. Mol. Biol. Rev. 62(4), 1094-1156 (1998).
15. Rottem S. Interaction of mycoplasma with host cells. Physiol. Rev. 83(20) 417-432 (2003).
16. Eaton MD, Meiklejohn G, van Herick W. Studies on the etiology of primary atypical pneumonia. A filterable agent transmissible to cotton rats, hamsters, and chick embryos. J. Exp. Med. 79, 649-668 (1944).
17. Chanock RM, Hayflick L, Barile MF. Growth on artificial medium of an agent associated with atypical pneumonia and its identification as a PPLO. Proc. Natl Acad. Sci. USA 48, 41-49 (1962).
18. Himmelreich R, Hilbert H, Plagens H, Pirkl E, Li BC, Herrmann R. Complete sequence analysis of the genome of the bacterium Mycoplasma pneumonie. Nucleic Acids Res. 24(22), 4420-4449 (1996).
19. Dandekar T, Huynen M, Regula JT et al. Re-annotating the Mycoplasma pneumoniae genome sequence: adding value, function and reading frames. Nucleic Acids Res. 28(17), 3278-3288 (2000).
20. Dallo SF, Baseman JB. Intracellular DNA replication and long-term survival of pathogenic mycoplasmas. Microb. Pathog. 29(5), 301-309 (2000).
21. Guarner F, Malagelada JR. Gut flora in health and disease. Lancet 361(9356), 512-519 (2003).
22. Acheson DW, Luccioli S. Microbial-gut interactions in health and disease. Mucosal immune response. Best Pract. Res. Clin. Gastroenterol. 18(2), 387-404 (2004).
23. Husebye E. The pathogenesis of gastrointestinal bacterial overgrowth. Chemotherapy 51 (Suppl. 1), 1-22 (2005).
24. Hull MW, Chow AW. Indigenous microflora and innate immunity of the head and neck. Infect. Dis. Clin. North Am. 21(2), 265-282 (2007).
25. Noah ND. Mycoplasma infection in the United Kingdom: 1967-73. Br. Med. J. 2(5918), 544-546 (1974).
26. Foy HM, Kenny GE, Cooney MK, Allan ID. Long-term epidemiology of infections with Mycoplasma pneumoniae. J. Infect. Dis. 139(6), 681-687 (1979).
27. Pönkä A. Occurrence of serologically verified Mycoplasma pneumoniae infections in Finland and in the Scandinavia in 1970-1977. Scan. J. Infect. Dis. 12(1), 27-31 (1980).
28. Lind K, Benzon MW, Jensen JS, Clyde WA Jr. A seroepidemiological study of Mycoplasma pneumoniae infections in Denmark over the 50-year period 1946-1995. Eur. J. Epidemiol. 13(5), 581-586 (1997).
29. Rastawicki W, Kaluzewski S, Jagielski M. Occurrence of serologically verified Mycoplasma pneumoniae infections in Poland in 1970-1995. Eur. J. Epidemiol. 14(1), 37-40 (1998).
30. Hauksdottir GS, Love A, Sigurdardottir V, Jonsson T. Outbreaks of Mycoplasma pneumoniae infections in Iceland 1987 to 1997: a ten and a half years review. Eur. J. Epidemiol. 15(1), 95-96 (1999).
31. Ito I, Ishida T, Osawa M et al. Culturally verified Mycoplasma pneumoniae pneumonia in Japan: a long-term observation from 1979-1999. Epidemiol. Infect. 127(2), 365-367 (2001).
32. Hong JY, Nah SY, Nam SG, Choi EW, Park JY, Lee WJ. Occurence of Mycoplasma pneumoniae pneumonia in Seoul, Korea, from 1986-1995. J. Korean Pediatr. Soc. 40(6), 607-612 (1997).
33. Kang KS, Woo HO. Pattern of occurrence of Mycoplasma pneumoniae pneumonia in admitted children; southern central Korea, from 1989 to 2002. J. Korean Pediatr. Soc. 46(4), 474-479 (2003).
34. Foy FM. Infections caused by Mycoplasma pneumoniae and possible carrier state in different population of patients. Clin. Infect. Dis. 17(Suppl.), S37-S46 (1993).
35. Dorigo-Zetsma JW, Wilbrink B, van der Nat H, Bartelds AI, Heijnen MI, Dankert J. Results of molecular detection of Mycoplasma pneumoniae among patients with acute respiratory infection and in their household contacts reveals children as human reservoirs. J. Infect. Dis. 183(4), 15, 675-678 (2001).
36. Brunner H, Prescott B, Greenberg H, James WD, Horswood RL, Chanock RM. Unexpectedly high frequency of antibody to Mycoplasma pneumoniae in human sera as measured by sensitive techniques. J. Infect. Dis. 135(4), 524-530 (1977).
37. Pönkä A, Ukonen P. Age-related prevalence of complement-fixating antibody to Mycoplasma pneumoniae during an 8-year period. J. Clin. Microbiol. 17(4), 571-575 (1983).
38. Nir-paz R, Michael-Gayego A, Ron M, Block C. Evaluation of eight commercial tests for Mycoplasma pneumoniae antibodies in the absence of acute infection. Clin. Micobiol. Infect.12(7), 685-688 (2006).
39. Principi N, Esposito S, Blasi F, Allegra L; Mowgli study group. Role of Mycoplasma pneumoniae and Chlamydia pneumoniae in children with community-acquired lower respiratory tract infections. Clin. Infect. Dis. 32(9), 1281-1289 (2001).
40. Layani-Milon MP, Gras I, Valette M et al. Incidence of upper respiratory tract Mycoplasma pneumoniae infections among outpatients in Rhône-Alpes, France, during five successive winter periods. J. Clin. Microbiol. 37(6), 1721-1726 (1999).
41. Koff RS. Clinical manifestations and diagnosis of hepatitis A virus infection. Vaccine 10 (Suppl. 1), S15-S17 (1992).
42. Lee KY, Lee HS, Hong JH et al. Roxithromycin treatment of scrub typhus (tsutsugamushi disease) in children. Pediatr. Infect. Dis. J. 22(2), 130-133 (2003).
43. Li AM, Ng PC. Severe acute respiratory syndrome (SARS) in neonates and children. Arch. Dis. Child. Fetal Neonatal Ed. 90(6), F461-F465 (2005).
44. Cherrick I, Karayalcin G, Lanzkowsky P. Transient erythroblastopenia of childhood. Prospective study of fifty patients. Am. J. Pediatr. Hematol. Oncol. 16(4), 320-324 (1994).
45. Bux J, Behrens G, Jaeger G, Welte K. Diagnosis and clinical course of autoimmune neutropenia in infancy: analysis of 240 cases. Blood 91(1), 181-186 (1998).
46. Blanchette VS, Carcao M. Childhood acute immune thrombocytopenic purpura: 20 years later. Semin. Thromb. Hemost. 29(6), 605-617 (2003).
47. Kilic SS, Tezcan I, Sanal O, Metin A, Ersoy F. Transient hypogammaglobulinemia of infancy: clinical and immunological features of 40 new cases. Pediatr. Int. 42(6), 647-650 (2000).
48. Lee KY, Han JW, Lee JS. Kawasaki disease may be a hyperimmune reaction of genetically-susceptible children to variants of normal environmental flora. Med. Hypotheses 69(3), 642-651 (2007).
49. Dorigo-Zetsma JW, Verkooyen RP, van Helden HP, van der Nat H, van den Bosch JM. Molecular detection of Mycoplasma pneumoniae in adults with community-acquired pneumonia requiring hospitalization. J. Clin. Microbiol. 39(3), 1184-1186 (2001).
50. File TM Jr, Tan JS, Plouffe JF. The role of pathogens: Mycoplasma pneumoniae, Chlamidia pneumoniae, and Legionella pheumophilia in respiratory infection. Infect. Dis. Clin. North Am. 12(3), 569-592 (1998).
51. Lee SJ, Lee MG, Jeon MJ, Jung KS, Lee HK, Kishimoto T. Atypical pathogens in adult patients admitted with community-acquired pneumonia in Korea. Jpn. J. Infect. Dis. 55(5), 157-159 (2002).
52. Su CJ, Chavoya A, Dallo SF, Baseman JB. Sequence divergency of the cytadhesin gene of Mycoplasma pneumoniae. Infect. Immun. 58(8), 2669-2674 (1990).
53. Sasaki T, Kenri T, Okazaki N et al. Epidemiological studies of Mycoplasma pneumoniae infections in Japan based on PCR-restriction fragment length polymorphism of the P1 cytadhesin gene. J. Clin. Microbiol. 34(2), 447-449 (1996).
54. Dumke R, Catrein I, Herrmann R, Jacobs E. Preference, adaptation and survival of Mycoplasma pneumoniae subtypes in an animal model. Intern. J. Med. Microbiol. 294(2-3), 149-155 (2004).
55. Matsuoka M, Narita M, Okazaki N et al. Characterization and molecular analysis of macrolide-resistant Mycoplasma pneumoniae clinical isolates obtained in Japan. Antimicob. Agents Chemother. 48(12), 4624-4630 (2004).
56. Suzuki S, Yamazaki T, Narita M et al. Clinical evaluation of macrolide-resistant Mycoplasma pneumoniae. Antimicob. Agents Chemother. 50(2), 709-712 (2006).
57. Denny FW, Clyde WA Jr, Glezen WP. Mycoplasma pneumonia disease: clinical spectrum, pathophysiology, epidemiology, and control. J. Infect. Dis. 123(1), 74-92 (1971).
58. Collier AM. Attachment by mycoplasmas and its role in disease. Rev. Infect. Dis. 5(Suppl. 4), S685-S691 (1983).
59. Dallo SF, Kannan TR, Blaylock MW, Baseman JB. Elongation factor Tu and E1 P subunit of pyruvate dehyd rogenase complex act as fibronectin binding protein in Mycoplasma pneumoniae. Mol. Microbiol. 46(4), 1041-1051 (2002).
60. Almagor M, Yatziv S, Kahane I. Inhibition of host cell catalase by Mycoplasma pneumoniae: a possible mechanism for cell injury. Infect. Immun.41(1), 251-256 (1983).
61. Kannan TP, Baseman JB. ADP-ribosylating and vacuolating cytotoxin of Mycoplasma pneumoniae represents unique virulence determinants among bacterial pathogens. Proc. Natl. Acad. Sci. USA 103(17), 6724-6729 (2006).
62. Ohtani N, Miyata M. Identification of a novel nucleoside triphosphate from mycoplasma mobile: a prime candidate motor for gliding motility. Biochem. J. 403(1), 71-77 (2007).
63. Totapally BR, Walsh WT. Pneumococcal bacteremia in childhood: a 6-year experience in a community hospital. Chest 113(5), 1207-1214 (1998).
64. Dallaire F, Ouellet N, Bergeron T et al. Microbiological and inflammatory factors associated with the development of pneumococcal pneumonia. J. Infect. Dis. 184(3), 292-300 (2001).
65. Smith MW, Schmidt JE, Rehg JE, Orihuela CJ, McCullers JA. Induction of pro- and anti-inflammatory molecules in a mouse model of pneumococcal pneumonia after influenza. Comp. Med. 57(1), 82-89 (2007).
66. Rahman SM, Eto H, Morshed SA, Itakura H. Giant cell pneumonia: light microscopy, immunohistochemical, and ultrastructural study of an autopsy case. Utrastruct. Pathol. 20(6), 585-591 (1996).
67. Tse GM, To KF, Chan PK et al. Pulmonary pathological features in corona virus associated severe acute respiratory syndrome (SARS). J. Clin. Pathol. 57(3), 260-265 (2004).
68. Griffin DE, Ward BJ, Esolen LM. Pathogenesis of measles virus infection: a hypothesis for altered immune responses. J. Infect. Dis. 170(Suppl. 1), S24-S31 (1994).
69. Kaplan LJ, Daum RS, Smaron M, McCarthy CA. Severe measles in immunocompromised patients. JAMA 267(9), 1237-1241 (1992).
70. Narita M, Tanaka H, Abe S, Yamada S, Kubota M, Togashi T. Close association between pulmonary disease manifestation in Mycoplasma pneumoniae infection and enhanced local production of interleukin-18 in the lung, independent of γ interferon. Clin. Diagn. Lab. Immunol. 7(6), 909-914 (2000).
71. Yang J, Hooper WC, Phillips DJ, Talkington DF. Cytokines in Mycoplasma pneumoniae infections. Cytokine Growth Factor Rev. 15(2-3), 157-168 (2004).
72. Hardy RD, Jafri HS, Olsen K, Wordemann M, Hatfield J, Rogers BB. Elevated cytokine and chemokine levels and prolonged pulmonary airflow resistance in a murine Mycoplasma pneumoniae model: a micobiologic, histologic, immunologic, and respiratory plethymographic profile. Infect. Immun. 69(6), 3869-3876 (2001).
73. Esposito S, Droghetti R, Bosis S, Claut L, Maechisio P, Principi N. Cytokine secretion in children with acute Mycoplasma pneumoniae infection and wheeze. Pediatr. Pulmonol. 34(2), 122-127 (2002).
74. Michelow IC, Katz K, MaCracken GH, Hardy RD. Systemic cytokine profile in children with community-acquired pneumonia. Pediatr. Pulmonol. 42(7), 640-645 (2007).
75. Hoffmann JA, Kafatos FC, Janeway CA, Ezekowitz RA. Phylogenetic perspective in innate immunity. Science 284(5428), 1313-1318 (1999).
76. Takeda K, Akira S. Toll-like receptors in innate immunity. Int. Immunol. 17(1), 1-14 (2005).
77. Mühlradt PF, Mess M, Meyer H, Süssmuth R, Jung G. Isolation, structure elucidation, and synthesis of a macrophage stimulatory lipopeptide from mycoplasma ferentance acting at picomolar concentration. J. Exp. Med. 185(11), 1951-1958 (1997).
78. Shimizu T, Kida Y, Kuwano K. A dipalmitoylated lipoprotein from Mycoplasma pneumoniae activates NF-κB through TLR1, TLR2, and TLR 6. J. Immunol. 175(7), 4641-4646 (2005).
79. Biberfeld G, Sterner G. Effect of Mycoplasma pneumoniae infection on cell-mediated immunity, Infection 4(Suppl. 1), 17-20 (1976).
80. Sabato AR, Cooper DM, Thong YH. Transitory depression of immune function following Mycoplasma pneumoniae infection in children. Pediatr. Res. 15(5), 813-816 (1981).
81. Tanaka H, Koba H, Honma S, Sugaye F, Abe S. Relationships between radiological pattern and cell mediated immune response in Mycoplasma pneumoniae pneumonia. Eur. Respir. J. 9(4), 669-672 (1996).
82. Nahm CH, Cho EY, Lee KY, Kang JH, Lee BC. A comparative study of Mycoplasma pneumoniae pneumonia according to age. J. Korean Pediatr. Infect. Dis. 12(1), 135-139 (2005).
83. Lee KY, Lee HS, Hur JK et al. Clinical features of measles according to age in a measles epidemic. Scand. J. Infect. Dis. 37(6-7), 471-475 (2005).
84. Starr S, Berkovich S. Effects of measles, γ-globulin-modified measles and vaccine measles on the tuberculin test. N. Engl. J. Med. 270 (7), 386-391 (1964).
85. Peiris JS, Chu CM, Cheng VC et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet 361 (9371), 1767-1772 (2003).
86. Noriega ER, Simberkoff MS, Gilroy FJ, Rahal JJ. Life-threatening Mycoplasma pneumoniae pneumonia. JAMA 229(11), 1471-1472 (1974).
87. Holt S, Ryan WF, Epstein EJ. Severe mycoplasma pneumonia. Thorax 32(1), 112-115 (1977).
88. Radisic M, Torn A, Gutierrez P, Defranchi HA, Pardo P. Severe acute lung injury caused by Mycoplasma pneumoniae: potential role for steroid pulses in treatment. Clin. Infect. Dis. 31(6), 1507-1511 (2000).
89. Klement E, Talkington DF, Wasserzug O et al. Identification of risk factors for infection in an outbreak of Mycoplasma pneumoniae respiratory tract disease. Clin. Infect. Dis. 43(10), 1239-1245 (2006).
90. Denny FW, Taylor-Robinson D, Allison C. The role of thymus-dependent immunity in Mycoplasma pulmonis infection of mice. J. Med. Microbiol. 5(3), 327-336 (1972).
91. Taylor G. Immunity to mycoplasma infections of the respiratory tract: a review. J. Royal. Soc. Med. 72(7), 520-526 (1979).
92. Tanaka H, Honma S, Abe S, Tamura H. Effects of IL-2 and cyclosporin A on pathologic features in mycoplasma pneumonia. Am. J. Respir. Crit. Care Med. 154(6), 1908-1912 (1996).
93. Jacobs E, Stuhlert A, Drews M et al. Host reactions to Mycoplasma pneumoniae infections in guinea-pigs preimmunised systemically with the adhesion of this pathogen. Microb. Pathog. 5(4), 259-265 (1988).
94. Cimolai N, Cheong ACH, Morrison BJ, Taylor GP. Protective and harmful immunoreactivity after Mycoplasma pneumoniae reinfection and vaccination. Vaccine 14(15), 1479-1483 (1996).
95. Dajani AS, Clyde WA Jr, Denny FW. Experimental infection with Mycoplasma pneumoniae (Eaton's agent). J. Exp. Med. 121(5), 1071-1087 (1965).
96. Opitz O, Pietsch K, Ehlers, Jacobs E. Cytokine gene expression in immune mice reinfected with Mycoplasma pneumoniae: the role of T cell subsets in aggravating the inflammatory response. Immunobiology 196(5), 575-587 (1996-1997).
97. Llibre JM, Urban A, Garcia E, Carrasco, MA, Murcia C. Bronchiolotis obliterance organizing pneumonia associated with acute Mycoplasma pneumoniae infection. Clin. Infect. Dis. 25(6), 1340-1342 (1997).
98. Rollins S, Colby T, Clayton F. Open lung biopsy in Mycoplasma pneumoniae pneumonia. Arch. Pathol. Lab. Med. 110(1), 34-41 (1986).
99. Vuori-Holopainen E, Salo E, Saxen H et al. Etiologic diagnosis of childhood pneumonia by use of transthoracic needle aspiration and modern microbiological methods. Clin. Infect. Dis. 34(3), 583-590 (2002).
100. Cimolai N. Corticosteroids and complicated Mycoplasma pneumoniae infection. Pediatr. Pulmonol. 41(10), 1008-1009 (2006).
101. Tai DY. Pharmacologic treatment of SARS: current knowledge and recommendations. Ann. Acad. Med. Singap. 36(6), 438-443 (2007).
102. Carter MJ. A rationale for using steroids in the treatment of severe cases of H5N1 avian influenza. J. Med. Microbiol. 56(Pt 7), 875-883 (2007)
103. Gnarpe J, Lundbäck A, Sundelöf B, Gnarpe H. Prevalence of Mycoplasma pneumoniae in subjectively healthy individuals. Scand. J. Infect. Dis. 24(2), 161-164 (1992).
104. Buchwald DS, Blaser MJ. A review of human salmonellosis: II. Duration of excretion following infection with nontyphi Salmonella. Rev. Infect. Dis. 6(3), 345-356 (1984).
105. Glebe D. Recent advances in hepatitis B virus research: a German point of view. World J. Gastroenterol. 13(1), 8-13 (2007).
106. Samore MH, Magill MK, Alder SC et al. High rates of multiple antibiotic resistance in Streptococcus pneumoniae from healthy children living in isolated rural communities: association with cephalosporin use and intrafamilial transmission. Pediatrics 108(4), 856-865 (2001).
107. Jain A, Kumar P, Awasthi S. High nasopharyngeal carriage of drug resistant Streptococcus pneumoniae and Haemophilus influenzae in north Indian schoolchildren. Trop. Med. Int. Health 10(3), 234-249 (2005).
108. McIntosh K. Pathogenesis of severe acute respiratory infections in the developing world: respiratory syncitial viruses and parainfluenza viruses. Rev. Infect. Dis. 13(Suppl. 6), S492-S500 (1991).
109. Foy HM, Kenny GE, McMahan R, Mansy AM. Mycoplasma pneumoniae pneumonia in an urban area. Five years of surveillance. JAMA 214(9), 1666-1672 (1970).
110. Mundy LM, Oldach D, Auwaerter PG et al. Implication for macrolide treatment in community-acquired pneumonia. Hopkins CAP Team. Chest 113(5), 1201-1206 (1998).
111. Shefet D, Robenshotock E, Paul M, Leibovici L. Empiric antibiotic coverage of atypical pathogens for community acquired pneumonia in hospitalized adults. Cochrane Database Syst. Rev. 18(2), CD004418 (2005).
112. Marc E, Chaussain M, Moulin F et al. Reducing lung diffusion capacity after Mycoplasma pneumoniae pneumonia. Pediatr. Infect. Dis. J. 19(8), 706-710 (2000).
113. Nisar N, Guleria R, Kumar S, Chand-Chawla T, Ranjan Biwa N. Mycoplasma pneumoniae and its role in asthma. Postgrad. Med. J. 83(976), 100-104 (2007).
114. Neumayr L, Lennette E, Kelly D et al. Mycoplasma disease and acute chest syndrome in sickle cell disease. Pediatrics 112(1), 87-97 (2003).
115. Fernald GW. Immunologic mechanisms suggested in the association of M. pneumoniae infection and extrapulmonary disease: a review. Yale J. Biol. Med. 56(5-6), 475-479 (1983).
116. Tsiodras S, Kelesidis I, Kelsidis T, Stamboulis E, Giamarellou H. Central nervous system manifestations of Mycoplsma pneumoniae infections. J. Infect. 51(5), 343-354 (2005).
117. Christie LJ, Honarmand S, Talkington DF et al. Pediatric encephalitis: what is the role of Mycoplasma pneumoniae? Pediatrics 120(2), 305-313 (2007).
118. John SD, Ramanathan J, Swischuk LE. Spectrum of clinical and radiographic findings in pediatric mycoplasma pneumonia. Radiographics 21(1), 121-131 (2001).
119. Osborne D. Radiologic appearance of viral disease of the lower respiratory tract in infant and children. Am. J. Radiol. 130(1), 29-33 (1978).
120. Wildin SR, Chonmaitree T, Swischuk LE. Roentgenographic features of common pediatric viral respiratory tract infections. Am J. Dis. Child. 142(1), 43-46 (1988).
121. Kim EA, Lee KS, Primack SL et al. Viral pneumonias in adults: radiologic and pathologic findings. Radiographics 22(Spec. issue), S137-S149 (2002).
122. Nambu A, Saito A, Araki T et al. Chlamydia pneumoniae: comparison with findings of Mycoplasma pneumoniae and Streptococcus pneumonia at thin-section CT. Radiology 238(1), 330-338 (2006).
123. George RB, Weill H, Rasch JR, Mogabgab WJ, Ziskind MM. Roentgenographic appearance of vital and mycoplasmal pneumonias. Am. Rev. Resp. Dis. 96(6), 1144-1150 (1967).
124. Korppi M, Don M, Valent F, Canciani M. The value of clinical features in differentiating between viral, pneumococcal and atypical bacterial pneumcnia in children. Acta Paediatr. 97(7), 943-947 (2008).
125. Shon JW, Park SC, Choi YH et al. Atypical pathogens as etiologic agents in hospitalized patients with community-acquired pneumonia in Korea: a prospective multi-center study. J. Korean. Med. Sci. 21(4), 602-607 (2006).
126. Clyne B, Olshaker JS. The C-reactive protein. J. Emerg. Med. 17(6), 1019-1025 (1999).
127. Pietitjean J, Vabret A, Gouarin S, Freymuth F. Evaluation of four commercial immunoglobulin G (IgG)-and IgM-specific enzyme immunoassays for diagnosis of Mycoplasma pneumoniae infections. J. Clin. Microbiol. 40(1), 167-171 (2002).
128. Beersma MF, Dirven K, van Dam AP, Templeton KE, Claas ECJ, Goossens H. Evaluation of 12 commercial tests and the complementary fixation test for Mycoplasma pneumoniae-specific immunoglobulin G (IgG) and IgM antibodies, with PCR used as the "gold standard" J. Clin. Microbiol. 43(5), 2277-2285 (2005).
129. Lee KY, Lee HS, Hur JK, Kang JH, Lee BC. The changing epidemiology of hospitalized pediatric patients in three measles outbreaks. J. Infect. 54(2), 167-172 (2007).
130. Pruzanski W, Katz A. Cold agglutinins: antibodies with biological diversity. Clin. Immunol. Rev. 3(1), 131-168 (1984).
131. Griffin JP. Rapid screening for cold agglutinins in pneumonia. Ann. Intern. Med. 70(4), 701-705 (1969).
132. Ngiam TE, Yap HK, Low PS et al. A rapid screening test in Mycoplasma pneumoniae infection. J. Singapore Pediatr. Soc. 22(1-4), 81-83 (1980).
133. Shankar EM, Kumarasamy N, Balakrishnan P et al. Seroprevalence of acute Mycoplasma pneumoniae infection HIV infected patients with pulmonary complaints in Chennai, southern India. J. Infect. 53(5), 325-330 (2006).
134. Moon SN, Lee MH, Lee KY, Lee JS. The diagnostic antibodies and polymerase chain reaction in Mycoplasma pneumoniae pneumonia. Presented at: The 57th Annual Fall Meeting of the Korean Pediatr Society, Seoul, Korea, 19-20 October, 2007 (Abstract 241).
135. Waits KB, Thacker WL, Talkington DF. The value of culture and serology for detection of Mycoplasma pneumoniae infections in the clinical laboratory in the age of molecular diagnostics. Cli. Microbiol. Newslett. 23(1), 123-129 (2001).
136. Loens K, Ursi D, Goossens H, Leven M. Molecular diagnosis of Mycoplasma pneumoniae respiratory tract infections. J. Clin. Microbiol. 41(11) 4915-4923 (2003).
137. Daxboeck F, Krause R, Weinsch C. Laboratory diagnosis of Mycoplasma pneumoniae infection. Clin. Microbiol. Infect. 9(4), 263-273 (2003).
138. Bernet C, Garret M, de Barbeyrac B, Bebear C, Bonnet J. Detection of Mycoplasma pneumoniae by using the polymerase chain reaction. J Clin. Microbiol. 270(11), 2492-2496 (1989).
139. Nadal D, Bossart W, Zucol F et al. Community-acquired pneumonia in children due to Mycoplasma pneumoniae: diagnostic performance of a seminested 16S rDNA-PCR. Diagn. Microbial. Infect. Dis. 39(1), 15-19 (2001).
140. Morozumi M, Ito A, Murayama SY et al. Assessment of real-time PCR for diagnosis of Mycoplasma pneumoniae pneumonia in pediatric patients. Can. J. Microbiol. 52(2) 125-129 (2006).
141. Weigl JA, Puppe B, Gröndahl B, Schimitt HJ. Epidemiological investigation of nine respiratory pathogens in hospitalized children in Germany using multiplex reverse-transcriptase polymerase chain reaction. Eur. J. Clin. Microbiol. Infect. Dis. 19(5), 336-343 (2000).
142. Räy R, Rönkkö E, Kleemola M. Sample type is crucial to the diagnosis of Mycoplasma pneumoniae pneumonia by PCR. J. Med. Microbiol. 54(3), 287-291 (2005).
143. Kingston JR, Chanock RM, Musfun MA. Eaton agent pneumonia. JAMA 176(4), 118-123 (1961).
144. Rasch JR, Mogabgab WJ. Therapeutic effect of erythromycin on Mycoplasma pneumoniae pneumonia. Anthmicrob. Agents Chemother. 5, 633-639 (1965).
145. McCracken GH Jr. Current status of antibiotic treatment for Mycoplasma pneumoniae infections. Pediatr. Infect. Dis. 5(1), 167-171 (1986).
146. Manfredi R, Januzzi C, Mantero E et al. Clinical comparative studiy of azithromycin versus erythromycin in the treatment of acute respiratory tract infections in children. J. Chemother. 4(6), 364-370 (1992).
147. Block S, Hedrick J, Hammerschlag MR, Cassell GH, Craft JC. Mycoplasma pneumoniae and Chlamidia pneumoniae in pediatric community-acquired pneumonia: comparative efficacy and safety of clarithromycin vs. erythromycin ethylsuccinate. Peadiatr. Infect. Dis. J. 14(6), 471-477 (1995).
148. Hardy RD, Rios AN, Chaver-Bueno S et al. Antimicrobial and immunologic activities of charithromycin in a murine model of Mycoplasma pneumonia-induced pneumonia. Antimicrob. Agents Chemother. 47(5), 1614-1620 (2003).
149. File TM Jr, Segreti J, Dunber L et al. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxim axetil in treatment of adults with community-acquired pneumonia. Antimicrob. Agents Chemother. 41(9), 1965-1972 (1997).
150. Gavranich JB, Chang AB. Antibiotics for community acquired lower respiratory tract infections (LRTI) secondary to Mycoplasma pneumoniae in children. Cochrane Database Sys. Rev. 20(3), CD004875 (2005).
151. Wibbel I, Muniz L, Ahmed A et al. Etiology and treatment of community-acquired. pneumoma in ambulatory children. Pediatr. Infect. Dis. J. 18(2), 98-104 (1999).
152. Harris JA, Kolokathis A, Cambell M, Cassel GH, Hammerschulag MR. Safety and efficacy of azithromycin in the treatment of community-acquired pneumonia in children. Pediatr. Infect. Dis. J. 17(10), 865-871 (1998).
153. Othman N, Isaacs, Kesson A. Mycoplasma pneumoniae infections in Australian children. J. Pediatr. Child Health 41, 671-676 (2005).
154. Daxboeck F, Eisl B, Burghuber C, Memarsadeghi M, Assadian O, Smeck G. Fetal Mycoplasma pneumoniae pneumonia in a previously healthy 18-year-old girl. Wien. Klin. Wochenschr. 119(6), 379-384 (2007).
155. McGowan JE Jr, Chesney PJ, Crossley KB, LaForce FM. Guidelines for the use of systemic glucocorticosteroids in the management of selected infections. J. Infect. Dis. 165(1), 1-13 (1992).
156. Sibéril S, Elluru S, Negi VS et al. Intravenous immunoglobulin in autoimmune and inflammatory disease: more than mere transfer of antibodies. Transfus. Apher. Sci. 37(1), 102-107 (2007).
157. Lee KY, Lee JS. Immunoglobulin G has a role for systemic protein modulation in vivo: a new concept of protein homeostasis. Med. Hypotheses 67(4), 848-855 (2006).
158. Wang JL, Ho MY, Shen EY. Mycoplasma pneumoniae infection associated with hemolytic anemia: report of one case. Acta Paediatr. Taiwan 45(5), 293-295 (2004).
159. Steer AC, Starr M, Kornberg AJ. Bickerstaff brainstem encephalitis associated with Mycoplasma pneumoniae infection. J. Child Neurol. 21(6), 544-534 (2006).
160. Bream-Rouwenhorst HR, Beltz EA, Ross MB, Moores KG. Recent developments in the management of acute respiratory distress syndrome in adults. Am. J. Health Syst. Pharm. 65(1), 29-36 (1998).
161. Kim CY, Chung CY, Kim JS, Kim WS, Park Y, Koh YY. Late abnormal findings on high-resolution computed tomography after mycoplasma pneumonia. Pediatrics 105(2), 372-378 (2000).
162. Stokes D, Sigler A, Khouri NF, Talamo, RC. Unilateral hyperlucent lung (Swyer-James syndrome) after severe Mycoplasma pneumoniae infection. Am. Rev. Respir. Dis. 117(1), 145-152 (1978).